NeuroPace (NPCE) Projected to Post Earnings on Wednesday

NeuroPace (NASDAQ:NPCE) is expected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $21.85 million for the quarter.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.14 million. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Price Performance

Shares of NPCE stock opened at $13.37 on Tuesday. The firm’s 50 day moving average price is $11.56 and its two-hundred day moving average price is $11.37. The stock has a market cap of $437.91 million, a PE ratio of -13.37 and a beta of 2.04. NeuroPace has a 52-week low of $5.45 and a 52-week high of $15.11. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NPCE. Wells Fargo & Company lifted their price objective on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. UBS Group started coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price for the company. Finally, Cantor Fitzgerald increased their price target on NeuroPace from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.20.

Insiders Place Their Bets

In related news, major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Martha Morrell sold 78,334 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. This represents a 48.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 22.20% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.